Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-SURG: Neoadjuvant Cemiplimab and Chemotherapy in High-Risk Stage 3 NSCLC
NCT06449313Phase 2Recruiting
- Sponsor
- Georgetown University
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Georgetown University. Primary endpoint: Pathologic complete response rate at 12 weeks. Started Nov 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06449313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449313.